Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

Journal of Dermatology

Volumn 39, Issue 3, 2012, Pages 242-252

  Igarashi, Atsuyuki ^a   Kato, Takeshi ^b   Kato, Mai ^b   Song, Michael ^c   Nakagawa, Hidemi ^d  

^a Kanto Teishin Hospital   (Japan)

^b Janssen Pharmaceutical KK   (Japan)

^c CENTOCOR INC   (United States)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

biologics; interleukin 12 23p40; Japanese; psoriasis; ustekinumab

Indexed keywords

PLACEBO; USTEKINUMAB;

ADULT; ALLERGIC RHINITIS; ARTICLE; BASAL CELL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HAY FEVER; HEART DISEASE; HUMAN; INFECTION; INJECTION SITE REACTION; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE INDEX; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TINEA PEDIS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADULT; ANTIBODIES, MONOCLONAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; JAPAN; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84857623641     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01347.x     Document Type: Article

References (38)

1. Chandran V, Raychaudhuri SP,. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010; 34: J314-J321.
2. Schön MP, Boehncke WH,. Psoriasis. N Engl J Med 2005; 352: 1899-1912. (Pubitemid 40627816)
3. Jee SH, Tsai TF, Tsai WL, Liaw SH, Chang CH, Hu CY,. HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. Br J Dermatol 1998; 139: 978-983.
4. Yip SY,. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984; 10: 965-968. (Pubitemid 14111149)
5. Kawada A, Tezuka T, Nakamizo Y, et al., Japanese Society for Psoriasis Research. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003; 31: 59-64. (Pubitemid 36286960)
6. Naldi L, Griffiths CE,. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615. (Pubitemid 40571289)
7. Igarashi A,. Japan-the epidemiology and current treatment of psoriasis. IPC Psoriasis Review 2010; 6: 7.
8. Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD,. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 1995; 33: 44-52.
9. Thaçi D,. Long-term data in the treatment of psoriasis. Br J Dermatol 2008; 159 (Suppl 2): 18-24.
10. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS,. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005; 52 (3 Pt 1): 434-444.
11. Torii H, Nakagawa H, Japanese Infliximab Study Investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-49.
12. Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
13. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
14. Trinchieri G,. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146. (Pubitemid 37328691)
15. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957. (Pubitemid 47300009)
16. Aggarwal R, Manadan AM, Poliyedath A, Sequeira W, Block JA,. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 2009; 36: 914-917.
17. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-5708. (Pubitemid 34556153)
18. Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996; 93: 14002-14007.
19. Krueger GG, Langley RG, Leonardi C, et al., CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-592. (Pubitemid 46220818)
20. Leonardi CL, Kimball AB, Papp KA, et al., PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674. (Pubitemid 351671883)
21. Papp KA, Langley RG, Lebwohl M, et al., PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
22. Griffiths CE, Strober BE, van de Kerkhof P, et al., ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
23. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
24. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216. (Pubitemid 24194579)
25. Finlay AY,. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867. (Pubitemid 40704922)
26. Rich P, Scher RK,. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-212. (Pubitemid 36951265)
27. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
28. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D,. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141-155. (Pubitemid 29093257)
29. Finlay AY, Kelly SE,. Psoriasis-an index of disability. Clin Exp Dermatol 1987; 12: 8-11. (Pubitemid 17223839)
30. Holm S,. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
31. Medical Dictionary for Regulatory Activities Japanese Edition web site:. Accessed December 10, 2010.
32. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-146.
33. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-206. (Pubitemid 47241785)
34. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-290. (Pubitemid 46175676)
35. Tsunemi Y, Saeki H, Nakamura K, et al. Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 2002; 30: 161-166. (Pubitemid 36159027)
36. Chang YT, Chou CT, Yu CW, et al. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol 2007; 156: 899-905. (Pubitemid 46642859)
37. Nair RP, Stuart PE, Kullavanijaya P, et al. Genetic evidence for involvement of the IL23 pathway in Thai psoriatics. Arch Dermatol Res 2010; 302: 139-143.
38. Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; doi:.